Forxiga’s acute renal impairment warning added in Korea too

Acute renal impairment will be added in approval standards of antidiabetic SGLT-2 inhibitors, ‘Forxiga(dapagliflozin)’ and ‘Invokana(canagliflozin).’

According to the Ministry of Food and Drug Safety(MFDS) on the 22^nd, it prepared for an amendment to approval standards of drugs containing canagliflozin and dapagliflozin, based on reviewing the U.S. FDA’s safety information.

The MFDS plans to ...